Page last updated: 2024-11-12
atractyligenine
Description
atractyligenine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
atractyligenin : A diterpenoid isolated from coffee silverskin. It inhibits cutaneous photoaging. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
ID Source | ID |
PubMed CID | 11045436 |
CHEBI ID | 196975 |
SCHEMBL ID | 3226198 |
MeSH ID | M0434674 |
Synonyms (7)
Synonym |
atractyligenin |
CHEBI:196975 |
(2r,4r,4ar,6ar,7s,9r,11as,11br)-2,7-dihydroxy-11b-methyl-8-methylidenetetradecahydro-6a,9-methanocyclohepta[a]naphthalene-4-carboxylic acid |
(2beta,4alpha,15alpha)-2,15-dihydroxy-19-norkaur-16-en-18-oic acid |
atractyligenine |
SCHEMBL3226198 |
(1r,4r,5r,7r,9r,10s,13r,15s)-7,15-dihydroxy-9-methyl-14-methylidenetetracyclo[11.2.1.01,10.04,9]hexadecane-5-carboxylic acid |
Roles (1)
Role | Description |
plant metabolite | Any eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (4)
Class | Description |
carbotetracyclic compound | A carbopolyclic compound comprising of four carbocyclic rings. |
dihydroxy monocarboxylic acid | Any hydroxy monocarboxylic acid carrying at least two hydroxy groups. |
ent-kaurane diterpenoid | A diterpenoid compound having an ent-kaurane skeleton. |
tetracyclic diterpenoid | A diterpenoid with a tetracyclic skeleton. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (9)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 1 (11.11) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (22.22) | 29.6817 |
2010's | 5 (55.56) | 24.3611 |
2020's | 1 (11.11) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.45
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 12.45 (24.57) | Research Supply Index | 2.30 (2.92) | Research Growth Index | 4.75 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 9 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |